The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.
OBJECTIVE
The purpose of this study was to determine the potential effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.


METHODS
Twelve patients received single oral 1.5 mg doses of zalcitabine alone and during probenecid treatment (500 mg at 8 and 2 hours before and 4 hours after zalcitabine dosing) in an open-label, randomized two-way crossover study with a one-week washout period between treatments. Serial blood and urine samples were collected over a 24 hour period and assayed for zalcitabine by a modified GC/MS method.


RESULTS
Coadministration of probenecid with zalcitabine resulted in a decrease in mean (%CV) renal clearance of zalcitabine from 310 (28%) ml/min when zalcitabine was given alone to 180 (22%) ml/min with probenecid and a prolonged half-life from 1.7 hours to 2.5 hours. Mean AUCs increased from 59 ng.h/ml when zalcitabine was given alone to 91 ng.h/ml when given with probenecid. Considering the short half-life of zalcitabine (1-3 hours) relative to its dosing schedule, the pharmacokinetic changes observed in this study are not expected to result in significant accumulation during chronic dosing.


CONCLUSIONS
The results of this study show that co-administration of probenecid with zalcitabine results in a moderate decrease in renal clearance of zalcitabine due to inhibition of renal tubular secretion and a 50% increase in drug exposure. Although well tolerated in this single-dose study, patients taking this combination should be monitored closely for signs of toxicity and dosage reduction should be considered if warranted.
Massarella
J W
JW
Department of Clinical Pharmacology, Hoffman-La Roche Inc., Nutley, New Jersey 07110, USA.
Nazareno
L A
LA
Passe
S
S
Min
B
B
D000284:Administration, Oral; D000328:Adult; D000998:Antiviral Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011339:Probenecid / Q000494:pharmacology*; D014528:Uricosuric Agents / Q000493:pharmacokinetics*; D016047:Zalcitabine / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D000998:Antiviral Agents; D014528:Uricosuric Agents; D016047:Zalcitabine; D011339:Probenecid